euro adhoc: Intercell AG / Personnel / Intercell AG appoints Thomas Lingelbach (E)

Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement.


Intercell AG (VSE, "ICLL") today announced the recruitment of Thomas Lingelbach as Chief Operating Officer of Intercell and Managing Director of Intercell Biomedical Ltd. (Scotland), the operating site for the commercial production of Intercells Japanese Encephalitis Vaccine. Within his function beginning on October 1st, 2006, he will play a pivotal role in establishing Intercell´s commercial manufacturing as well as its further production and process development.

He started his professional career in the pharma industry in 1989 at Hoechst AG, Frankfurt (Germany). From 2001 till Chiron's acquisition by Novartis in April 2006, he served as Vice President Industrial Operations in Chiron Vaccines' Executive Committee as well as Managing Director for Chiron-Behring GmbH & Co. KG in Germany. Most recently he has been significantly involved in Novartis' Vaccines and Diagnostics integration activities acting as General Manager and Managing Director for its German Vaccines Operations.

Thomas Lingelbach successfully transformed Chiron Vaccines' industrial operations into a globally integrated function with center of excellence sites in Germany, Italy, the UK and India. He implemented key processes for technology industrialization, supply chain and industrial product management. In his capacity he played an integral part in getting Fluvirin back on the market in 2005, when he led the remediation efforts at the Liverpool site in close collaboration with MHRA and FDA. Furthermore, he enabled the Marburg site to become the first commercially viable flu cell culture manufacturing facility.

"Thomas Lingelbach's profound experience, his leadership competences and prominent position in the human vaccine field is another example of Intercell's philosophy to build a top-class worldwide business with outstanding staff", states Gerd Zettlmeissl, Intercell's Chief Executive Officer.

About Intercell AG

Intercell AG is a biotechnology company focused on the research, development, manufacturing and future commercialization of innovative vaccines for the prevention and treatment of infectious diseases, for which there exists a substantial unaddressed medical need. Intercell develops antigens and immunizers (adjuvants), which are derived from its proprietary technology platforms and has in-house GMP manufacturing capability. Intercell has strategic partnerships with a number of global pharmaceutical companies, including Novartis, Sanofi Pasteur S.A., Merck & Co., Inc., SciGen Ltd., the Statens Serum Institut and Kirin Brewery Co. Ltd. Intercell has a broad development pipeline with a vaccine product candidate for Japanese Encephalitis in Phase III clinical trials, where Novartis will be the strategic partner for marketing and distribution, a vaccine product candidate for Hepatitis C in Phase II, partnered vaccine candidates for Tuberculosis and S. aureus, which are in Phase I, and more than five other product candidates focused on infectious diseases in pre-clinical development. Intercell is listed on the Vienna stock exchange under the symbol "ICLL".

For picture download of Thomas Lingelbach or more information, please visit the press section on

Further inquiry note:
Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303

end of announcement euro adhoc

emitter: Intercell AG
Campus Vienna Biocenter 6
A-1030 Wien
phone: +43 1 20620-0
FAX: +43 1 20620-800
ISIN: AT0000612601
stockmarkets: official market: Wiener Börse AG
sector: Biotechnology
language: English